Results 281 to 290 of about 22,609,350 (346)

Gene Therapy and Gene Editing in Type 1 Diabetes: CRISPR‐Based β‐Cell Replacement and Treg Immune Modulation Approaches

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 5476-5491, July 2026.
ABSTRACT Background Type 1 diabetes mellitus (T1DM) is a chronic autoimmune disease marked by the destruction of pancreatic β‐cells, resulting in lifelong dependence on exogenous insulin. Despite advances in insulin delivery and glucose monitoring technologies, patients remain at risk for acute and long‐term complications, underscoring the need for ...
Tzu‐Min Lin, Hui‐Fang Chang, Tzu‐Ching Lin, Cheng‐Han Lin, Yu‐Ling Sun, Chih‐Sheng Lin   +5 more
wiley   +1 more source

Mucous Membrane Pemphigoid After Anti‐PD‐1 Therapy: Risk‐Stratified Management and Treatment Outcomes

International Journal of Dermatology, Volume 65, Issue 7, Page 1376-1382, July 2026.
ABSTRACT Mucous membrane pemphigoid (MMP) following anti‐programmed cell death‐1 (PD‐1) therapy is rare but increasingly reported. Management of high‐ and low‐risk MMP in this setting and the potential oncologic trade‐offs remain poorly defined. We performed a narrative synthesis of all published cases of anti‐PD‐1‐associated MMP, following MEDLINE ...
Serena Dienes, Negar Esfandiari, Steven Daveluy   +2 more
wiley   +1 more source

Myocarditis induced by a novel bifunctional PD-1/CTLA-4 combination antibody: a case report and literature review. [PDF]

BMC Cardiovasc Disord
Wei C, Tang C, Zhang Y, Tang Y, Liu Y, Tan Y, Fu Y.   +6 more
europepmc   +1 more source

Preclinical and Virtual Models of Mucosal Melanoma: Bridging Translational Gaps in a Rare and Lethal Cancer

Pigment Cell &Melanoma Research, Volume 39, Issue 4, July 2026.
Integrated physical and virtual modeling provides a scalable framework to overcome sample scarcity, recapitulate mucosal melanoma biology, and accelerate translational discovery toward precision medicine. ABSTRACT Mucosal melanoma (MM) is a rare and lethal subtype of melanoma, disproportionately affecting Asian populations and exhibiting distinct ...
Xiangjie Jin, Yuhan Zhang, Yuantai Zhu, Zhiyuan Zhang, Chaoji Shi   +4 more
wiley   +1 more source

Meeting Report From the 2025 Cure Ocular Melanoma (CURE OM) Global Science Meeting, Amsterdam, the Netherlands, October 2025

Pigment Cell &Melanoma Research, Volume 39, Issue 4, July 2026.
ABSTRACT The 2025 Cure Ocular Melanoma (CURE OM) Global Science Meeting took place in Amsterdam, The Netherlands on October 25th, 2025. Several promising drug candidates are in development; however, there is still an urgent need for better prevention, detection, and treatment of uveal melanoma.
Andrew E. Aplin, Katherina Alsina, Allison S. Betof, Joseph Birkett, Marcus O. Butler, George Cole Jr., Rizwan Haq, Florian A. Karreth, Vinit B. Mahajan, Rahul Marpadga, Prithvi Mruthyunjaya, Paul Nathan, Jonas A. Nilsson, Gary Palmer, Joseph J. Sacco, Takami Sato, Sarah Stanhope, Pang‐ning Teng, Kyleigh LiPira   +18 more
wiley   +1 more source

Unsupervised Flow Cytometry Reveals a Constant Shift Towards Activated CD4+ T Cell Subsets in APECED

Scandinavian Journal of Immunology, Volume 104, Issue 1, July 2026.
APECED is caused by mutations of AIRE that impair negative selection in the human thymus. Using our optimized unsupervised workflow, we reveal that APECED patients show increased activation of T cells and alterations to their Treg pool as well as a novel T cell population not found among healthy controls.
Joonatan Mattila, Nelli Heikkilä, Iivo Hetemäki, Joonatan Borchers, Outi Mäkitie, Saila Laakso, T Petteri Arstila   +6 more
wiley   +1 more source

Single versus repeated intravenous oncolytic reovirus infusions: Implications for immune modulation and rationalised scheduling of therapy in hepatocellular carcinoma

International Journal of Cancer, Volume 158, Issue 12, Page 3252-3267, 15 June 2026.
What's new? Oncolytic viruses are a promising immunotherapeutic approach against many malignancies. However, it is unclear whether repeated doses have improved therapeutic value or may trigger greater side effects, especially in patients with hepatocellular carcinoma whose liver is chronically damaged.
Karen J. Scott, Emma J. West, Rebecca J. Brownlie, Fay Ismail, Christy Ralph, Thomas Heineman, Matt Coffey, Alan A. Melcher, Alison Taylor, Salvatore Papa, Adel Samson   +10 more
wiley   +1 more source

CTLA-4-Ig therapy preserves cardiac function following myocardial infarction with reperfusion. [PDF]

Cardiovasc Res
Noonan J, Prijaya SA, Bienvenu LA, Dayawansa NH, Michla M, Bongcaron V, Sharma P, Song Y, Huang A, Barbaro-Wahl A, Huang Y, Nguyen H, Nguyen A, Murphy AJ, Zhang Y, Lee MKS, Johnson CJ, Watson AMD, Thomas AC, McFadyen JD, Donner DG, Wang X, Peter K.   +22 more
europepmc   +1 more source

Enterococcus faecalis KU-EF-004 enhances efficacy of anti-CTLA-4 immunotherapy for colorectal cancer via dendritic cell activation and gut microbiota modulation. [PDF]

BMC Immunol
Yamazaki T, Minami A, Kitagawa K, Yanase S, Ueki H, Shirakawa T.   +5 more
europepmc   +1 more source